Technology area: Medical Devices & Mechanical Engineering
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Orbicular Pharmaceutical Technologies Private Limited has 3 pending office actions in Medical Devices & Mechanical Engineering. The matters involve 3 distinct examiners and 2 distinct art units, showing that the pending work is distributed among examiners while remaining within a limited number of technical groups.
RICCI, CRAIG D is the busiest examiner, with 1 pending matter. Counsel should compare the claims and office-action grounds across the assigned matters, particularly where the same art unit may influence examination treatment. The record supports coordinated terminology and disclosure review, but the separate examiner assignments make individualized arguments and response timing important.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| WHITROCK, ZACHARIAH KIRBY | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836057 | PHARMACEUTICAL COMPOSITION OF LIFITEGRAST AND LOTEPREDNOL ETABONATE | RICCI, CRAIG D | — |
| 18724799 | SELF-ADMINISTRATION INJECTION DEVICE FOR RISPERIDONE | WHITROCK, ZACHARIAH KIRBY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836057 | PHARMACEUTICAL COMPOSITION OF LIFITEGRAST AND LOTEPREDNOL ETABONATE | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836057 | PHARMACEUTICAL COMPOSITION OF LIFITEGRAST AND LOTEPREDNOL ETABONATE | RICCI, CRAIG D | — | §102§103§112 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18724799 | SELF-ADMINISTRATION INJECTION DEVICE FOR RISPERIDONE | WHITROCK, ZACHARIAH KIRBY | 3783 | §103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrbicular Pharmaceutical Technologies Private Limited has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Craig D Ricci has the most, with 1 of Orbicular Pharmaceutical Technologies Private Limited's pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
